Evidence map›Paper›PMID 33545064›Full record

ReviewCancer cell2021

Melanoma models for the next generation of therapies.

E Elizabeth Patton, Kristen L Mueller, David J Adams, Niroshana Anandasabapathy, Andrew E Aplin, Corine Bertolotto, Marcus Bosenberg, Craig J Ceol, Christin E Burd, Ping Chi and 26 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers.

0numbers the graph read from it
0cells of the map it votes in
114citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

114 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Violacein-Loaded Outer Membrane Vesicles fromACS biomaterials science & engineering · 2025
    Article
  16. Article
  17. VersatileProceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  18. Article
  19. Article
  20. Article

54 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors.

E Elizabeth PattonMRC Human Genetics Unit and Cancer Research UK Edinburgh Centre, MRC Institute of Genetics & Molecular Medicine, The University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK. Electronic address: e.patton@igmm.ed.ac.uk.
Kristen L MuellerMelanoma Research Alliance, 730 15th Street NW, Washington, DC 20005, USA. Electronic address: kmueller@curemelanoma.org.
David J AdamsExperimental Cancer Genetics, Wellcome Sanger Institute, Hinxton, Cambridge CB10 1SA, UK.
Niroshana AnandasabapathyDepartment of Dermatology, Meyer Cancer Center, Program in Immunology and Microbial Pathogenesis, Weill Cornell Medicine, New York, NY 10026, USA.
Andrew E AplinDepartment of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Corine BertolottoUniversité Côte d'Azur, Nice, France; INSERM, Biology and Pathologies of Melanocytes, Team 1, Equipe Labellisée Ligue 2020, Centre Méditerranéen de Médecine Moléculaire, Nice, France.
Marcus BosenbergDepartments of Dermatology, Pathology, and Immunobiology, Yale University, New Haven, CT, USA.
Craig J CeolProgram in Molecular Medicine and Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, MA, USA.
Christin E BurdDepartments of Molecular Genetics, Cancer Biology, and Genetics, The Ohio State University, Biomedical Research Tower, Room 918, 460 W. 12th Avenue, Columbus, OH 43210, USA.
Ping ChiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Graduate School of Medical Sciences, Cornell University, New York, NY, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Meenhard HerlynThe Wistar Institute, Philadelphia, PA, USA.
Sheri L HolmenDepartment of Surgery, University of Utah Health Sciences Center, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.
Florian A KarrethDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Charles K KaufmanWashington University School of Medicine, Department of Medicine, Division of Oncology, Department of Developmental Biology, McDonnell Science Building, 4518 McKinley Avenue, St. Louis, MO 63110, USA.
Shaheen KhanDepartment of Pathology, UT Southwestern Medical Center, Dallas, TX, USA.
Sebastian KoboldCenter of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU, Munich, Germany; Member of the German Center for Lung Research (DZL), German Center for Translational Cancer Research (DKTK), partner site Munich, Munich, Germany.
Eleonora LeucciLaboratory for RNA Cancer Biology, Department of Oncology, LKI, KU Leuven, 3000 Leuven, Belgium; Trace, Department of Oncology, LKI, KU Leuven, 3000 Leuven, Belgium.
Carmit LevySackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.
David B LombardDepartment of Pathology, Institute of Gerontology, and Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.
Amanda W LundRonald O. Perelman Department of Dermatology and Department of Pathology, NYU Grossman School of Medicine, New York, NY 10016, USA.
Kerrie L MarieLaboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Jean-Christophe MarineLaboratory for Molecular Cancer Biology, Center for Cancer Biology, VIB, Leuven, Belgium; Laboratory for Molecular Cancer Biology, Department of Oncology, KU Leuven, Leuven, Belgium.
Richard MaraisCRUK Manchester Institute, The University of Manchester, Alderley Park, Macclesfield SK10 4TG, UK.
Martin McMahonDepartment of Dermatology & Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Carla Daniela Robles-EspinozaLaboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Campus Juriquilla, Boulevard Juriquilla 3001, Santiago de Querétaro 76230, Mexico; Wellcome Sanger Institute, Hinxton, Cambridgeshire CB10 1SA, UK.
Ze'ev A RonaiCancer Center, Sanford Burnham Medical Discovery Institute, La Jolla, CA 92037, USA.
Yardena SamuelsDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
Maria S SoengasSpanish National Cancer Research Centre, 28029 Madrid, Spain.
Jessie VillanuevaThe Wistar Institute, Molecular and Cellular Oncogenesis Program, Philadelphia, PA, USA.
Ashani T WeeraratnaDepartment of Biochemistry and Molecular Biology, Johns Hopkins Bloomberg School of Public Health, and Department of Oncology, Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.
Richard M WhiteDepartment of Cancer Biology & Genetics and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Iwei YehDepartments of Dermatology and Pathology, University of California, San Francisco, CA, USA.
Jiyue ZhuDepartment of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, USA.
Leonard I ZonStem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute, Howard Hughes Medical Institute, Harvard Medical School, Harvard Stem Cell Institute, Stem Cell and Regenerative Biology Department, Harvard University, Boston, MA, USA.
Marc S HurlbertMelanoma Research Alliance, 730 15th Street NW, Washington, DC 20005, USA.
Glenn MerlinoCenter for Cancer Research, NCI, NIH, 37 Convent Drive, Bethesda, MD 20892, USA. Electronic address: gmerlino@helix.nih.gov.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Yale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI DAVID L RIMM · 1985 to 2026
$85.0M
Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9M
UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6M
Yale SPORE in Skin CancerP50CA121974 · NCI · YALE UNIVERSITY · PI DAVID F STERN · 2006 to 2026
$43.9M
Targeting the MAP and PI3 Kinase Pathways in MelanomaP01CA114046 · NCI · WISTAR INSTITUTE · PI HERLYN, MEENHARD F, WEERARATNA, ASHANI T · 2008 to 2023
$37.1M
Transcriptional mechanisms and melanomaP01CA163222 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Kai W Wucherpfennig · 2013 to 2026
$25.3M
Targeting Oncogenic Pathways in Genetically Complex SarcomasP50CA217694 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Marc Ladanyi · 2018 to 2026
$21.5M
Tumor Assessment CoreP01CA128814 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI SMITH, JEFFREY W · 2009 to 2020
$19.1M
Research Project 2 - Targeting Melanoma Tumor Survival and Apoptotic MachineryU54CA224070 · NCI · WISTAR INSTITUTE · PI Michael Davies · 2017 to 2026
$13.9M
Project 4P50CA225450 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI OSMAN, IMAN, WEBER, JEFFREY S · 2019 to 2025
$12.5M
Preclinical Mouse Models for Studying Immune Checkpoint Inhibitor ResponseZIABC011167 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MERLINO, GLENN T. · 2009 to 2024
$12.4M
Cancer Research UK 17240Cancer Research UK 19279Cancer Research UK 22902Cancer Research UK A22902Cancer Research UK A27412Cancer Research UK C5759/A29061Medical Research Council MC_UU_00007/9Medical Research Council MR/S01473X/1NCI NIH HHS DP2 CA174499NCI NIH HHS DP2 CA186572NCI NIH HHS K22 CA197058NCI NIH HHS P01 CA114046NCI NIH HHS P01 CA128814NCI NIH HHS P01 CA163222NCI NIH HHS P01 CA206980NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA010815NCI NIH HHS P30 CA016359NCI NIH HHS P30 CA042014NCI NIH HHS P50 CA121974NCI NIH HHS P50 CA217694NCI NIH HHS P50 CA225450NCI NIH HHS R01 CA103846NCI NIH HHS R01 CA121118NCI NIH HHS R01 CA176839NCI NIH HHS R01 CA182635NCI NIH HHS R01 CA196278NCI NIH HHS R01 CA196566NCI NIH HHS R01 CA196660NCI NIH HHS R01 CA204002NCI NIH HHS R01 CA207935NCI NIH HHS R01 CA212376NCI NIH HHS R01 CA215733NCI NIH HHS R01 CA216101NCI NIH HHS R01 CA216846NCI NIH HHS R01 CA226888NCI NIH HHS R01 CA228216NCI NIH HHS R01 CA229215NCI NIH HHS R01 CA232246NCI NIH HHS R01 CA232256NCI NIH HHS R01 CA237213NCI NIH HHS R01 CA238163NCI NIH HHS R01 CA238237NCI NIH HHS R01 CA238317NCI NIH HHS R01 CA240633NCI NIH HHS R01 CA244660NCI NIH HHS R01 CA253977NCI NIH HHS R03 CA227349NCI NIH HHS R13 CA250294NCI NIH HHS R35 CA197465NCI NIH HHS R37 CA240914NCI NIH HHS U01 CA233096NCI NIH HHS U01 CA238728NCI NIH HHS U54 CA224070NIAMS NIH HHS R01 AR070234NIEHS NIH HHS R21 ES032305NIGMS NIH HHS R01 GM071725NIGMS NIH HHS R01 GM101171Wellcome TrustWellcome Trust 100282/Z/12/Z
6 · The paper itself

Abstract

There is a lack of appropriate melanoma models that can be used to evaluate the efficacy of novel therapeutic modalities. Here, we discuss the current state of the art of melanoma models including genetically engineered mouse, patient-derived xenograft, zebrafish, and ex vivo and in vitro models. We also identify five major challenges that can be addressed using such models, including metastasis and tumor dormancy, drug resistance, the melanoma immune response, and the impact of aging and environmental exposures on melanoma progression and drug resistance. Additionally, we discuss the opportunity for building models for rare subtypes of melanomas, which represent an unmet critical need. Finally, we identify key recommendations for melanoma models that may improve accuracy of preclinical testing and predict efficacy in clinical trials, to help usher in the next generation of melanoma therapies.

Indexed as

Disease Models, AnimalAnimalsHumansImmunityImmunotherapyMelanomaSkin NeoplasmsTumor Microenvironmentanimal modelsdrug discoveryimmunotherapymelanomatargeted therapytherapeuticstumor microenvironment

Identifiers

PMID33545064
PMCPMC8378471

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.